Curiosity Diagnostics, owned by Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects
Curiosity Diagnostics – member of the Scope Fluidics S.A. Group – has completed the fifth stage of works…
The Management Board of Scope Fluidics SA has decided to extend the work on a panel for detecting…
The PCR|ONE system, developed by Scope Fluidics, a New Connect-listed company, has gained great interest from market representatives and journalists during one of the largest medical diagnostics conferences in the world, namely MedLab Middle East, held in Dubai.
Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects – has launched its own semi-automatic manufacturing line in Warsaw, which allows for independent production of chips. The manufacturing infrastructure is also capable of assembling PCR|ONE analyzers. This event is a part of the implementation of the milestone associated with the execution of pre-registration tests.
Curiosity Diagnostics – a member of the Scope Fluidics S.A. Capital Group – successfully completed the second series of pre-validation tests of the PCR|ONE system in ALAB laboratories. The results of the tests confirmed that the clinical parameters of bacteria detection s in compliance with the market standards and clinical requirements. The tests also proved the competitive advantage of the PCR|ONE system, i.e. a unique combination of time-efficiency and comprehensive character of the test for the presence of Staphylococcus aureus.
Curiosity Diagnostics – a company that belongs to the Scope Fluidics S.A. Capital Group – has announced that it has obtained a conditional decision from the European Patent Office on granting the patent for the patent application titled „Device for simultaneous and uniform thermal cycling of samples and uses thereof”.
Curiosity Diagnostics, a company belonging to the Scope Fluidics S.A. Capital Group, has completed the fourth stage of R&D works on the PCR|ONE system for automatic analysis of the genetic material of the bacterial and viral pathogens, unmatched on account of the speed and comprehensiveness of testing.
PCR|ONE and BacterOMIC, two innovative medical diagnostic systems developed by Scope Fluidics, a biotechnology company listed on NewConnect, are among the seven breakthrough medical solutions from around the world competing for the Disruptive Technology Award 2019 granted by the American Association for Clinical Chemistry (AACC), the world’s largest organization which brings together medical diagnostic specialists.
- PCR|ONE System receives European CE-IVD certificate for its MRSA/MSSA panel
- Scope Fluidics completes clinical trials of a rapid PCR|ONE genetic test for detecting Staphylococcus aureus and its drug-resistant variants (MRSA)
- Scope Fluidics has begun the certification tests on the MRSA panel
- Scope Fluids has finished preregistration tests on the SARS Cov-2 panel
- Scope Fluidics launches clinical tests of the PCR|ONE SARS-Cov-2 panel in the clinical environment